Morphic Therapeutic
OverviewSuggest Edit
Morphic Therapeutic operates as a biotechnology company. The company develops oral integrin drugs. It is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders, and immuno-oncology.
| Type | Public | |
| Founded | 2015 | |
| HQ | Waltham, US | Map |
| Website | morphictx.com |
Recent NewsAll News
- Morphic to Present at the Jefferies 2019 London Healthcare Conference
- Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
- Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
Morphic Therapeutic Office Locations
Morphic Therapeutic has an office in Waltham
Waltham, US (HQ)
35 Gatehouse Dr
Morphic Therapeutic Financials and Metrics
Morphic Therapeutic Revenue
Morphic Therapeutic's revenue was reported to be $3.36 m in FY, 2019
| USD | |
|---|---|
Revenue (FY, 2019) | 3.4m |
Net income (FY, 2019) | (23.8m) |
EBIT (FY, 2019) | (24.6m) |
Market capitalization (29-Nov-2019) | 484.1m |
Closing stock price (29-Nov-2019) | 15.9 |
Cash (30-Sept-2019) | 159.8m |
Morphic Therapeutic's current market capitalization is $484.1 m.
Annual
| USD | FY, 2017 | FY, 2018 |
|---|---|---|
Net Income | (16.9m) | (23.8m) |
Depreciation and Amortization | 434.0k | 539.0k |
Accounts Payable | 285.0k | 862.0k |
Cash From Operating Activities | (15.4m) | 7.6m |
| USD | Y, 2019 |
|---|---|
Revenue/Employee | 51.4k |
Financial Leverage | 1.6 x |
Morphic Therapeutic Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Morphic Security Corporation |
Morphic Therapeutic Online and Social Media Presence
250 Twitter followers
Morphic Therapeutic has 250 Twitter Followers. The number of followers has increased 3.4% month over month and increased 16% quarter over quarter
Morphic Therapeutic's Trends
Morphic Therapeutic Blogs
November 18, 2019
Morphic to Present at the Jefferies 2019 London Healthcare Conference
WALTHAM, Mass. , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni , M.D., president and chief executive
November 12, 2019
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
MORF-720, α v β 6 -targeted oral integrin inhibitor IND now anticipated in the second half of 2020 α 4 β 7 -targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020 Morphic ends third quarter of 2019 with favorable cash, cash equivalents and marketable securities of $252
June 14, 2019
Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors
WALTHAM, Mass. – June 14, 2019 – Morphic Therapeutic, a biotechnology company developing oral integrin therapies, today announced the appointment of former Gilead chief scientific officer and executive vice president of research and development, Norbert Bischofberger, Ph.D., to its Board of Director…
February 21, 2019
Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
Deal extends reach of Morphic discovery across all known human integrins Therapeutic potential of Morphic pipeline expanded by inclusion of both integrin inhibitor and activator research Collaboration facilitated by Johnson & Johnson Innovation, Boston WALTHAM, Mass. – February 21, 2019 – Morphi…
January 02, 2019
Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. – January 2, 2019 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019.
October 18, 2018
AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
Collaboration leverages Morphic’s unique platform for developing oral integrin drugs and AbbVie’s global development and commercialization capabilities
NORTH CHICAGO, Ill. and WALTHAM, Mass. – October 18, 2018 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic The…
Morphic Therapeutic Frequently Asked Questions
When was Morphic Therapeutic founded?
Morphic Therapeutic was founded in 2015.
How many employees does Morphic Therapeutic have?
Morphic Therapeutic has 76 employees.
What is Morphic Therapeutic revenue?
Latest Morphic Therapeutic annual revenue is $3.4 m.
What is Morphic Therapeutic revenue per employee?
Latest Morphic Therapeutic revenue per employee is $44.2 k.
Who are Morphic Therapeutic competitors?
Competitors of Morphic Therapeutic include Trefoil Therapeutics, Twist Bioscience and KinDex Pharmaceuticals.
Where is Morphic Therapeutic headquarters?
Morphic Therapeutic headquarters is located at 35 Gatehouse Dr, Waltham.
Where are Morphic Therapeutic offices?
Morphic Therapeutic has an office in Waltham.
How many offices does Morphic Therapeutic have?
Morphic Therapeutic has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies